Investors

Overview

Corporate Profile

Gamida Cell is an advanced cell therapy company committed to finding cures for patients with cancer and other serious diseases. We harness our NAM-enabled technology platform to create therapies with the potential to improve the course of cancer care.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Latest News

View All
Nov 23, 2022

Gamida Cell to Present Corporate Highlights at Multiple Upcoming Investor Conferences

Read More
Nov 21, 2022

Gamida Cell Provides Regulatory Update on Omidubicel

Read More
Nov 14, 2022

Gamida Cell Reports Third Quarter 2022 Financial Results and Provides Company Update

Read More
Nov 10, 2022

Gamida Cell to Present Corporate Highlights at the Jefferies London Healthcare Conference

Read More
Nov 07, 2022

Gamida Cell Announces the Date of Its Third Quarter 2022 Financial Results and Webcast

Read More
Nov 07, 2022

GDA-501, NAM enabled NK Cell Therapy, Demonstrates Promising Antitumor Activity Against HER2+ Cancers

Read More
Nov 03, 2022

Gamida Cell Announces Omidubicel Data To Be Presented as an Oral Presentation at 64th ASH Annual Meeting

Read More
Oct 10, 2022

Gamida Cell to Present Corporate Highlights at 2022 Cell & Gene Meeting on the Mesa

Read More
Sep 29, 2022

Long-Term Data from Omidubicel Phase 3 Trial Demonstrates Overall Survival and Sustainable Durable Outcomes for Patients with Blood Cancers at the Society of Hematologic Oncology Meeting

Read More
Sep 28, 2022

Gamida Cell Announces Pricing of Approximately $20 Million Public Offering of Ordinary Shares

Read More
Sep 28, 2022

Gamida Cell Announces Entry into Commitment Letter with Highbridge for $25 Million Financing

Read More
Sep 27, 2022

Gamida Cell Announces Launch of Public Offering of Ordinary Shares

Read More
Sep 19, 2022

Gamida Cell Appoints Abigail L. Jenkins as President and Chief Executive Officer, Bringing Broad Leadership Experience in Commercializing Innovative Therapies

Read More
Sep 12, 2022

Gamida Cell Presents Data Demonstrating the Impact of Transplantation with Omidubicel for Patients with Hematologic Malignancies at 2022 Cord Blood Connect Meeting

Read More
Aug 15, 2022

Gamida Cell Reports Second Quarter 2022 Financial Results and Provides Company Update

Read More
Aug 10, 2022

Gamida Cell Announces Dosing of First Patient in Company-Sponsored Phase 1/2 Study of NK Cell Therapy Candidate GDA-201

Read More
Aug 08, 2022

Gamida Cell Announces the Date of Its Second Quarter 2022 Financial Results and Webcast

Read More
Aug 01, 2022

Gamida Cell Announces FDA Acceptance of Biologics License Application for Omidubicel with Priority Review

Read More
Jun 13, 2022

Gamida Cell to Present Corporate Highlights at the JMP Securities Life Sciences Conference

Read More
Jun 10, 2022

Gamida Cell Appoints Ivan M. Borrello, M.D., Expert in Immuno-Oncology, Cell Therapies, and Bone Marrow Transplant to Board of Directors

Read More
Corporate Fact Sheet
Corporate Presentation

Investor & Media Contact

Heather DiVecchia
Director, Investor Relations and Corporate Communications
Gamida Cell Ltd.
IRPR@gamida-cell.com